Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant ADT + Enzalutamide + Abiraterone in Newly Diagnosed Prostate Cancer
NCT03860987Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2019
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide, abiraterone, piflufolastat f 18 in prostate cancer (PCa), sponsored by National Cancer Institute. Started Apr 2019; status: completed.
02
Drugs
enzalutamideabirateronepiflufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03860987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860987.